in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Lonza Signs API Manufacturing Deal with Elan
9:04 AM MST | December 8, 2011 | Deepti Ramesh
Biotechnology company Elan (Dublin) says it has entered into a manufacturing agreement with Lonza for the supply of the active pharmaceutical ingredient (API) for ELND005, which is being developed by Elan for the treatment of Alzheimer's...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee